These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 17378499)

  • 1. Question: is insulin glargine more effective?
    Kitowicz A; Criswell DF
    J Okla State Med Assoc; 2007 Jan; 100(1):26-7. PubMed ID: 17378499
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin therapy in elderly patients with type 2 diabetes: the role of insulin glargine.
    Janka HU
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():35-41. PubMed ID: 18577155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.
    Bradley C; Gilbride CJ
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():50-65. PubMed ID: 18577157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Patient satisfaction in diabetes mellitus--measures and results].
    Kohlmann T; Moock J
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S120-3; discussion S124-6. PubMed ID: 18686221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glargine (Lantus) and cancer risk.
    Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
    [No Abstract]   [Full Text] [Related]  

  • 8. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Putting insulin glargine and malignancies into perspective.
    Ehninger G; Schmidt AH
    Oncologist; 2009 Dec; 14(12):1169-74. PubMed ID: 20007644
    [No Abstract]   [Full Text] [Related]  

  • 10. Glargine insulin and high-protein-low-carbohydrate diet in cats with diabetes mellitus.
    Boari A; Aste G; Rocconi F; Dalessandri A; Vita S
    Vet Res Commun; 2008 Sep; 32 Suppl 1():S243-5. PubMed ID: 18685984
    [No Abstract]   [Full Text] [Related]  

  • 11. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
    Juhaeri J; Gao S; Dai WS
    Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin analogue usage in a haemodialysis patient with type 2 diabetes mellitus.
    Ersoy A; Ersoy C; Altinay T
    Nephrol Dial Transplant; 2006 Feb; 21(2):553-4. PubMed ID: 16221693
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G; Laurenti O; Moretti A
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-acting insulin analogues vs. human insulin for diabetes.
    Schooff M; Ehlers K
    Am Fam Physician; 2005 Sep; 72(5):805-7. PubMed ID: 16156336
    [No Abstract]   [Full Text] [Related]  

  • 16. Insulin glulisine in the treatment of allergy to rapid acting insulin and its rapid acting analogs.
    Mollar-Puchades MA; Villanueva IL
    Diabetes Res Clin Pract; 2009 Jan; 83(1):e21-2. PubMed ID: 19070911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes.
    Le Roith D
    Diabetes Metab Res Rev; 2007 Nov; 23(8):593-9. PubMed ID: 17922476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment: insulin strategies for type 2 diabetes mellitus.
    Davidson JA
    Ann Pharmacother; 2005 May; 39(5):975-6; author reply 976. PubMed ID: 15811902
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.